4 results
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinb and metformin, combined with gemcitabine in patients with metatastatic pancreatic…
To determine the dose limiting toxicity (DLT) and the maximum tolerated dose and recommended dose of the combination of everolimus orally once daily and metformin orally BID to patients with advanced solid tumors.
To study if the induction of skin barrier proteins, like FLG, by coal tar leads to an improved skin barrier repair and function in the absence of a chronic inflammatory component.
To investigate whether on demand dosing using population-based PK-models in VWD patients is reliable and feasible.